drugset
drugset / Trial / NCT03090412

Photodynamic Therapy With HPPH Compared to Standard of Care Surgery in Treating Patients With Oral Cavity Cancer

NCT03090412 ↗

Phase 2 Terminated 2 enrolled Roswell Park Cancer Institute National Cancer Institute (NCI) · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

This randomized phase II clinical trial studies how well photodynamic therapy with HPPH works compared to standard of care surgery in treating patients with oral cavity cancer. Photodynamic therapy can destroy or control disease by using a combination of drug, such as HPPH, and light and may be as effective as surgery in treating patients with oral cavity cancer.

Timeline

Start
2018-03-07
Primary completion
2021-08-01
Completion
2021-08-06

Outcome

Outcome not reported

Stopped (Enrollment): “low accrual”

Drugs

EvaluationDrugModalityDoseRoute
Subject 2-(1-HEXYLOXYETHYL)-2-DEVINYL PYROPHEOPHORBIDE-A Unknown — Intravenous

Indications

oral cavity squamous cell carcinoma